Pyxis Oncology, Inc. PYXS 深 滬
已收盤 04-02 16:00:00 美东时间
1.48
+0.010
+0.68%
華盛通- 最 高1.495
- 今 開1.43
- 成交量 19.58万股
- 最 低 1.40
- 昨 收 1.47
- 總市值 9299.02万
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 0.873
- 委 比 -81.93%
- 總股本 6283.12万
- 歷史最高 19.00
- 量 比 0.71
- 振 幅 6.46%
- 歷史最低 0.8332
- 每 手 1
- 風險率 1.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
03-24 19:06
Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.33) by 12.65 percent. This is a 50.85 percent increase over losses of $(0.59) per share from
03-23 19:12
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
2025-12-19 22:07
Pyxis Oncology shares are trading lower. The company announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin.
Pyxis Oncology shares are trading lower. The company announced preliminary data...
2025-12-18 22:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Stephens & Co. Maintains Overweight on Pyxis Oncology, Raises Price Target to $8
Stephens & Co. analyst Sudan Loganathan maintains Pyxis Oncology (NASDAQ:PYXS) with a Overweight and raises the price target from $5 to $8.
2025-11-24 22:04
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
